EyeGate receives FDA approval to initiate PRK pivotal study
By Akshay Kedari  Date: 2019-06-04

EyeGate receives FDA approval to initiate PRK pivotal study

EyeGate Pharmaceuticals, Inc. has reportedly received approval from the U.S. Food and Drug Administration to start photorefractive keratectomy or PRK pivotal study.

As per trusted sources, the FDA has determined that EyeGate provided adequate data to support the initiation of the clinical study and has asked the pharma company to make some alterations in the patient informed consent document before enrollment. Sources claim that the company will immediately address these changes and looks forward to enrollments starting this month.

Sources familiar with the knowledge of the matter cite Stephen From, Chief Executive Officer of EyeGate, to have said in a statement that the company is extremely pleased with the comments received from the FDA about the design of the company’s PRK pivotal study and plans to initiate enrollment at the earliest.

The company expects topline outcomes by the end of 2019, anticipating them to be positive, so that the de novo application for commercialization can be submitted soon, From claimed, adding that post the successful approval, the company’s OGB platform will be the United States’ foremost prescription Hyaluronic Acid eyedrop formulation presenting a huge opportunity for the company.

According to a reliable news report, EyeGate Pharmaceuticals Inc. stock spiked 20% as of June 3. The company’s stock has reportedly climbed $0.05 from the earlier closing price of $0.25 on a volume of 3,160,386 stocks.

For the record, EyeGate is a clinical-stage specialty pharmacological company dedicated to developing and commercializing drugs and therapeutics through its two proprietary platform technologies focused on the treatment of eye diseases and disorders.

The company’s OBG platform formed on a crosslinked thiolated CMHA-S, a modified form of the natural polymer hyaluronic acid, which is a gel that holds unique physical and chemical features such as hydrating and healing properties when applied to the ocular surface, reported sources. 

Source Credit
https://finance.yahoo.com/news/eyegate-receives-approval-fda-initiate-105500530.html

https://www.investorsobserver.com/market-intelligence-center/stock-update/is-eyegate-pharmaceuticals-eyeg-stock-a-strong-buy-following-fda-study-approval/


 

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Innovaccer unveils AI-enabled patient relationship management solution
Innovaccer unveils AI-enabled patient relationship management solution
By Akshay Kedari

Innovaccer, Inc., a healthcare company, has recently launched an AI (artificial intelligence) enabled patient relationship management solution. The new solution will streamline communication between the care teams and patients. In addition, the solu...

Geely Tech to rollout a smart battery swapping network across Jinan
Geely Tech to rollout a smart battery swapping network across Jinan
By Akshay Kedari

Geely Technology Group, a Chinese automobile manufacturer, and the Municipal Government of Jinan, China, have reportedly signed an all-round strategic cooperation deal to jointly develop a network of smart battery swapping service stations across Jin...

CStone Pharmaceuticals, Pfizer finalize a $200 million share sale deal
CStone Pharmaceuticals, Pfizer finalize a $200 million share sale deal
By Akshay Kedari

Chinese biotechnology company, CStone Pharmaceuticals has recently announced that it has completed the Share Subscription Agreement with Pfizer Inc. for its newly issued shares worth US$200 million. The move furthers the biotech’s multifaceted ...

Researchers bag $6Mn grant to study the link between Parkinson’s & aging
Researchers bag $6Mn grant to study the link between Parkinson’s & aging
By Akshay Kedari

A three-year grant worth $6 million, funded by the Michael J. Fox Foundation, was recently awarded to a collaborative research team from Michigan’s Van Andel Institute (VAI) and the University of Minnesota Medical School. The grant was given th...

EY announces availability of OpsChain Network Procurement solution
EY announces availability of OpsChain Network Procurement solution
By Akshay Kedari

Ernst & Young (EY), a global professional services network, has recently announced the availability of a first-of-its-kind OpsChain Network Procurement solution. The solution has been built on the company’s OpsChain platform. It will enabl...